Skip to Content

Otiprio Approval History

  • FDA approved: Yes (First approved December 10th, 2015)
  • Brand name: Otiprio
  • Generic name: ciprofloxacin
  • Dosage form: Otic Suspension
  • Previous name: AuriPro
  • Company: Otonomy, Inc.
  • Treatment for: Tympanostomy Tube Placement Surgery; Acute Otitis Externa

Otiprio (ciprofloxacin otic suspension) is a single-dose, physician-administered, sustained-exposure otic fluoroquinolone antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement surgery, and for the treatment of acute otitis externa due to Pseudomonas aeruginosa and Staphylococcus aureus.

Development History and FDA Approval Process for Otiprio

Mar  2, 2018Approval Otonomy Announces FDA Approval of Otiprio (ciprofloxacin otic suspension) for Acute Otitis Externa
Dec 11, 2015Approval FDA Approves Otiprio (ciprofloxacin otic suspension) for the Treatment of Pediatric Patients Undergoing Tympanostomy Tube Placement Surgery
Apr 28, 2015Otonomy Announces FDA Acceptance of AuriPro New Drug Application
Feb 26, 2015Otonomy Submits New Drug Application to the FDA for AuriPro

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.